WO2009117421A3 - Heterocyclic modulators of gpr119 for treatment of disease - Google Patents

Heterocyclic modulators of gpr119 for treatment of disease Download PDF

Info

Publication number
WO2009117421A3
WO2009117421A3 PCT/US2009/037408 US2009037408W WO2009117421A3 WO 2009117421 A3 WO2009117421 A3 WO 2009117421A3 US 2009037408 W US2009037408 W US 2009037408W WO 2009117421 A3 WO2009117421 A3 WO 2009117421A3
Authority
WO
WIPO (PCT)
Prior art keywords
gpr119
treatment
disease
heterocyclic modulators
modulators
Prior art date
Application number
PCT/US2009/037408
Other languages
French (fr)
Other versions
WO2009117421A2 (en
Inventor
Nicholas Smith
Celine Bonnefous
Steven P. Govek
Dongpei Wu
Anthony B. Pinkerton
Mehmet Kahraman
Travis Cook
Stewart A. Noble
Allen J. Borchardt
Thomas Prins
Original Assignee
Kalypsys, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kalypsys, Inc. filed Critical Kalypsys, Inc.
Publication of WO2009117421A2 publication Critical patent/WO2009117421A2/en
Publication of WO2009117421A3 publication Critical patent/WO2009117421A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

The present invention relates to compounds and methods which may be useful as inhibitors of GPR119 for the treatment or prevention of metabolic, cardiovascular, and metabolic diseases.
PCT/US2009/037408 2008-03-17 2009-03-17 Heterocyclic modulators of gpr119 for treatment of disease WO2009117421A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US3723908P 2008-03-17 2008-03-17
US61/037,239 2008-03-17
US9536208P 2008-09-09 2008-09-09
US61/095,362 2008-09-09

Publications (2)

Publication Number Publication Date
WO2009117421A2 WO2009117421A2 (en) 2009-09-24
WO2009117421A3 true WO2009117421A3 (en) 2010-01-07

Family

ID=41091499

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/037408 WO2009117421A2 (en) 2008-03-17 2009-03-17 Heterocyclic modulators of gpr119 for treatment of disease

Country Status (1)

Country Link
WO (1) WO2009117421A2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5467151B2 (en) * 2009-06-24 2014-04-09 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel compounds, pharmaceutical compositions and methods relating thereto
WO2011107494A1 (en) 2010-03-03 2011-09-09 Sanofi Novel aromatic glycoside derivatives, medicaments containing said compounds, and the use thereof
US20130109703A1 (en) 2010-03-18 2013-05-02 Boehringer Ingelheim International Gmbh Combination of a GPR119 Agonist and the DPP-IV Inhibitor Linagliptin for Use in the Treatment of Diabetes and Related Conditions
TW201209054A (en) 2010-05-28 2012-03-01 Prosidion Ltd Novel compounds
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
CN102070553B (en) * 2010-12-17 2013-08-07 西安瑞联近代电子材料有限责任公司 Synthesis method of thiazole-4-formaldehyde
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US9199975B2 (en) 2011-09-30 2015-12-01 Asana Biosciences, Llc Biaryl imidazole derivatives for regulating CYP17
CA2851087C (en) 2011-10-07 2019-09-24 Takeda Pharmaceutical Company Limited 1-arylcarbonyl-4-oxy-piperidine compounds useful for the treatment of neurodegenerative diseases
CN103087041B (en) * 2011-11-02 2014-06-18 中国中化股份有限公司 Use of diarylether-containing pyrazole-amide compounds as agricultural bactericide
JP2015522080A (en) 2012-07-11 2015-08-03 エルセリクス セラピューティクス インコーポレイテッド Compositions for reducing cardiovascular metabolic risk comprising statins, biguanides, and additional agents
WO2014016191A1 (en) * 2012-07-24 2014-01-30 Boehringer Ingelheim International Gmbh N-cyclopropyl-n-piperidinyl-amide derivatives and their use as gpr119 modulators
WO2014019967A1 (en) 2012-08-02 2014-02-06 Boehringer Ingelheim International Gmbh N-cyclopropyl-n-piperidinyl-amides, pharmaceutical compositions containing them and uses thereof
CN103254170B (en) * 2012-08-15 2014-04-30 山东省联合农药工业有限公司 Pyrazole ring-containing pesticide
CN102863356B (en) * 2012-10-11 2014-10-15 常州华南化工有限公司 Preparation method for 4-(4-methylphenoxy)cyanobenzene
CN103044393B (en) * 2012-11-30 2014-07-23 淮阴师范学院 Synthesis method of 1-(3-chloro-2-pyridyl)-1H-pyrazole-5-formate
SG11201507240RA (en) 2013-03-14 2015-10-29 Janssen Pharmaceutica Nv Benzo-fused heterocyclic derivatives useful as agonists of gpr120
CA2905729C (en) 2013-03-14 2021-11-09 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of gpr120
US10118922B2 (en) 2013-03-14 2018-11-06 Janssen Pharmaceutica Nv GPR120 agonists for the treatment of type II diabetes
CN103304561B (en) * 2013-06-21 2016-06-01 天津药物研究院 One class has the compound of anti thrombotic action
JP2017071553A (en) * 2014-02-25 2017-04-13 味の素株式会社 Novel compound having hetero atom-methylene-heterocycle structure
US9067898B1 (en) 2014-03-07 2015-06-30 Janssen Pharmaceutica Nv Isothiazole derivatives as GPR120 agonists for the treatment of type II diabetes
US8912227B1 (en) 2014-03-07 2014-12-16 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of GPR120
WO2015134038A1 (en) * 2014-03-07 2015-09-11 Janssen Pharmaceutica Nv Bicyclic pyrrole derivatives useful as agonists of gpr120
JO3705B1 (en) 2014-11-26 2021-01-31 Bayer Pharma AG Novel substituted indazoles, processes for preparation thereof, pharmaceutical preparations comprising them and use thereof for production of medicaments
CN104606189B (en) * 2015-01-08 2017-10-27 苏州大学 A kind of application of compound in mTOR inhibitors are prepared
US10280152B2 (en) 2015-03-30 2019-05-07 The General Hospital Corporation Imaging of glycogen synthase kinase 3
EP3195865A1 (en) 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Combinations of inhibitors of irak4 with inhibitors of btk
TW201701879A (en) 2015-04-30 2017-01-16 拜耳製藥公司 Combinations of IRAK4 inhibitors
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
WO2017207385A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Substituted 3-methylindazoles, methods for the production thereof, pharmaceutical preparations containing same, and use thereof for the production of medicaments
WO2017207340A1 (en) 2016-05-31 2017-12-07 Bayer Pharma Aktiengesellschaft Novel substituted benzimidazole, methods for the production thereof, pharmaceutical preparations containing same, and use thereof to produce medicaments
CA3025826A1 (en) 2016-06-01 2017-12-07 Bayer Pharma Aktiengesellschaft Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases
KR102547834B1 (en) 2016-06-01 2023-06-26 바이엘 애니멀 헬스 게엠베하 Substituted indazoles useful for the treatment and prevention of allergic and/or inflammatory diseases in animals
WO2018060174A1 (en) 2016-09-29 2018-04-05 Bayer Pharma Aktiengesellschaft Substituted benzimidazoles, pharmaceutical preparations containing same, and use of same to produce drugs
US11046683B2 (en) * 2016-12-15 2021-06-29 Ono Pharmaceutical Co., Ltd. Activator of TREK (TWIK RElated K+ channels) channels
CN106748992A (en) * 2017-01-04 2017-05-31 安徽国星生物化学有限公司 A kind of synthetic method of the trichloromethyl pyridine of 3 chlorine, 2 diazanyl 5
CN108017557B (en) * 2017-12-06 2020-11-24 中国科学院兰州化学物理研究所苏州研究院 Cyanidation method for preparing nitrile compound
PE20211001A1 (en) 2018-02-27 2021-06-01 Incyte Corp IMIDAZOPYRIMIDINES AND TRIAZOLOPYRIMIDINES AS INHIBITORS OF A2A / A2B
EP3774738A1 (en) 2018-04-06 2021-02-17 Aquinox Pharmaceuticals (Canada) Inc. Indene derivatives useful in treating pain and inflammation
JP7391046B2 (en) 2018-05-18 2023-12-04 インサイト・コーポレイション Fused pyrimidine derivatives as A2A/A2B inhibitors
GEP20237560B (en) 2018-07-05 2023-10-25 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (en) 2019-01-29 2024-01-21 美商英塞特公司 Pyrazolopyridines and triazolopyridines as a2a / a2b inhibitors
MX2022014505A (en) 2020-05-19 2022-12-13 Kallyope Inc Ampk activators.
CA3183575A1 (en) 2020-06-26 2021-12-30 Iyassu Sebhat Ampk activators
CN113040090A (en) * 2021-04-13 2021-06-29 南京医科大学 Method for constructing animal model of autism and corresponding application
CN113024389B (en) * 2021-05-24 2021-08-31 山东海利尔化工有限公司 Preparation method of substituted phenoxybenzylamine compound and pyrazole carboxamide compound
CA3227445A1 (en) 2021-08-31 2023-03-09 Eisai R&D Management Co., Ltd. Production method for synthetic intermediate of monocyclic pyridine derivative
EP4238970A1 (en) * 2022-03-03 2023-09-06 InterAx Biotech AG Modulators of ackr3 and uses thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1808168A1 (en) * 2005-01-10 2007-07-18 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
WO2007116229A1 (en) * 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic gpcr agonists
WO2008001931A2 (en) * 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
WO2008013322A1 (en) * 2006-07-27 2008-01-31 Mitsubishi Tanabe Pharma Corporation 1- (-d-glycopyranosyl) - 3 - (4-cyclopropylphenylmethyl) - 4 - halogeno indole derivatives and use thereof as sglt inhibitors.
WO2008025798A1 (en) * 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyridine compounds for treating gpr119 related disorders

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1808168A1 (en) * 2005-01-10 2007-07-18 Arena Pharmaceuticals, Inc. Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level
WO2007116229A1 (en) * 2006-04-06 2007-10-18 Prosidion Limited Heterocyclic gpcr agonists
WO2008001931A2 (en) * 2006-06-27 2008-01-03 Takeda Pharmaceutical Company Limited Fused cyclic compounds
WO2008013322A1 (en) * 2006-07-27 2008-01-31 Mitsubishi Tanabe Pharma Corporation 1- (-d-glycopyranosyl) - 3 - (4-cyclopropylphenylmethyl) - 4 - halogeno indole derivatives and use thereof as sglt inhibitors.
WO2008025798A1 (en) * 2006-08-30 2008-03-06 Biovitrum Ab (Publ) Pyridine compounds for treating gpr119 related disorders

Also Published As

Publication number Publication date
WO2009117421A2 (en) 2009-09-24

Similar Documents

Publication Publication Date Title
WO2009117421A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2010088518A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2010048149A3 (en) Heterocyclic modulators of gpr119 for treatment of disease
WO2008067219A3 (en) Quinazolinone modulators of tgr5
WO2008011560A3 (en) Benzothiophene inhibitors of rho kinase
WO2008033562A3 (en) Kinase inhibitor compounds
WO2010062863A3 (en) Compositions containing satiogens and methods of use
HRP20130357T1 (en) Novel compounds useful for the treatment of degenerative and inflammatory diseases.
MX353257B (en) Heterocyclic compounds useful as pdk1 inhibitors.
WO2007104053A3 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
IL212485A0 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
ZA200902374B (en) Compositions useful for the treatment of diabetes
WO2009055331A3 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
WO2009089494A3 (en) Pharmaceutical compositions
WO2010017541A3 (en) Compositions and methods for treatment of neurodegenerative disease
EA201100138A1 (en) 4-PHENOXYMETHYL-PIPERIDINES AS MODEL ACTIVITY GPR119
WO2010062377A3 (en) Methods and compositions for the detection and treatment of preeclampsia
EP2331093A4 (en) Compounds, compositions and methods for reducing toxicity and treating or preventing diseases
WO2009120810A3 (en) Neurodegenerative disorders
IL211313A0 (en) Compounds, compositions and methods for the treatment of ??-amyloid diseases and synucleinopathies
WO2011127048A3 (en) NON-HORMONAL STEROID MODULATORS OF NF-ĸB FOR TREATMENT OF DISEASE
WO2010065586A3 (en) Preparation of capecitabine
WO2010014739A3 (en) Heterocyclic modulators of tgr5
WO2011014520A3 (en) Compounds and compositions as modulators of gpr119 activity
WO2007137098A3 (en) Sulfonyl-substituted bicyclic compounds as modulators of ppar

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09721577

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09721577

Country of ref document: EP

Kind code of ref document: A2